Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

NCT06901505 is registered in ClinicalTrials.gov with Akebia Therapeutics as lead sponsor.

NCT NCT06901505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06901505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
Lead sponsor
Akebia Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
July 24, 2025
Completion date
August 12, 2026
Enrollment
353 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

anemia of chronic kidney disease